6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Discovery of a Ruthenium Complex for the Theranosis of Glioma through Targeting the Mitochondrial DNA with Bioinformatic Methods

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Glioma is the most aggressive and lethal brain tumor in humans. Mutations of mitochondrial DNA (mtDNA) are commonly found in tumor cells and are closely associated with tumorigenesis and progress. However, glioma-specific inhibitors that reflect the unique feature of tumor cells are rare. Here we uncover RC-7, a ruthenium complex with strong red fluorescence, could bind with glioma mtDNA and then inhibited the growth of human glioma cells but not that of neuronal cells, liver, or endothelial cells. RC-7 significantly reduced energy production and increased the oxidative stress in the glioma cells. Administration of RC-7 into mice not only could be observed in the glioma mass of brain by fluorescence imaging, but also obviously prevented the growth of xenograft glioma and prolonged mouse survival days. The findings suggested the theranostic application of a novel type of complex through targeting the tumor mtDNA.

          Related collections

          Most cited references40

          • Record: found
          • Abstract: found
          • Article: not found

          Mitochondria and Cancer.

          Decades ago, Otto Warburg observed that cancers ferment glucose in the presence of oxygen, suggesting that defects in mitochondrial respiration may be the underlying cause of cancer. We now know that the genetic events that drive aberrant cancer cell proliferation also alter biochemical metabolism, including promoting aerobic glycolysis, but do not typically impair mitochondrial function. Mitochondria supply energy; provide building blocks for new cells; and control redox homeostasis, oncogenic signaling, innate immunity, and apoptosis. Indeed, mitochondrial biogenesis and quality control are often upregulated in cancers. While some cancers have mutations in nuclear-encoded mitochondrial tricarboxylic acid (TCA) cycle enzymes that produce oncogenic metabolites, there is negative selection for pathogenic mitochondrial genome mutations. Eliminating mtDNA limits tumorigenesis, and rare human tumors with mutant mitochondrial genomes are relatively benign. Thus, mitochondria play a central and multifunctional role in malignant tumor progression, and targeting mitochondria provides therapeutic opportunities.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Glioma epigenetics: From subclassification to novel treatment options

            Gliomas are the most common malignant primary brain tumors, of which glioblastoma is the most malignant form (WHO grade IV), and notorious for treatment resistance. Over the last decade mutations in epigenetic regulator genes have been identified as key drivers of subtypes of gliomas with distinct clinical features. Most characteristic are mutations in IDH1 or IDH2 in lower grade gliomas, and histone 3 mutations in pediatric high grade gliomas that are also associated with characteristic DNA methylation patterns. Furthermore, in adult glioblastoma patients epigenetic silencing of the DNA repair gene MGMT by promoter methylation is predictive for benefit from alkylating agent therapy. These epigenetic alterations are used as biomarkers and play a central role for classification of gliomas (WHO 2016) and treatment decisions. Here we review the pivotal role of epigenetic alterations in the etiology and biology of gliomas. We summarize the complex interactions between "driver" mutations, DNA methylation, histone post-translational modifications, and overall chromatin organization, and how they inform current efforts of testing epigenetic compounds and combinations in preclinical and clinical studies.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics?

                Bookmark

                Author and article information

                Journal
                Int J Mol Sci
                Int J Mol Sci
                ijms
                International Journal of Molecular Sciences
                MDPI
                1422-0067
                19 September 2019
                September 2019
                : 20
                : 18
                : 4643
                Affiliations
                [1 ]College of Computer and Information Science, Southwest University, Chongqing 400715, China
                [2 ]College of Computer Science, Sichuan University, Chengdu 610065, China
                [3 ]College of Pharmaceutical Sciences, Southwest University, Chongqing 400715, China; fuchen0794@ 123456swu.edu.cn (C.F.); zhaozizhen0512@ 123456hotmail.com (Z.Z.); yixue6577@ 123456163.com (Y.H.); zw2678615937@ 123456163.com (W.Z.)
                Author notes
                [* ]Correspondence: fal@ 123456swu.edu.cn
                [†]

                The authors contributed equally to this work.

                Author information
                https://orcid.org/0000-0002-9924-0797
                https://orcid.org/0000-0001-9729-644X
                Article
                ijms-20-04643
                10.3390/ijms20184643
                6770666
                31546801
                6c9fc01a-7364-42d2-9db6-4ec5be043f29
                © 2019 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 03 August 2019
                : 17 September 2019
                Categories
                Article

                Molecular biology
                organometallic complexes,glioma,mtdna mutation,computation docking
                Molecular biology
                organometallic complexes, glioma, mtdna mutation, computation docking

                Comments

                Comment on this article